Trump Says Anthropic No Longer Seen as National Security Threat 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
PLYMOUTH, Minn., Jan. 28, 2016 -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the company plans to participate in the Leerink Partners 5th Annual Global Healthcare Conference in New York, NY.
Entellus Medical’s management is scheduled to present on Thursday, February 11, 2016 at 12:00pm ET. Interested parties can access the live audio webcast at http://www.entellusmedical.com. An archived presentation will be available on the website for 30 days.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients. The Entellus Medical platform of products provides physicians with solutions to aid in the diagnosis and treatment of patients suffering from chronic sinusitis. Its XprESS family of products is used by ENT physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation. When used as a stand-alone therapy, Entellus Medical's balloon sinus dilation products are the only devices proven in a sufficiently powered prospective, multicenter, randomized, controlled trial to be as effective as functional endoscopic sinus surgery ("FESS"). Patients treated with Entellus Medical's products in this trial in the ENT physician's office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than patients receiving FESS. In addition to its XprESS line of products, Entellus Medical has recently introduced additional products designed to aid in the diagnosis, treatment and post-operative care of patients suffering from chronic sinusitis. For more information, please visit the Company's website at www.entellusmedical.com.
Carrie Mendivil 415-513-1283 [email protected]
